Endothelin receptor antagonists (ERAs) targeting the endothelin B receptor (EDNRB) exhibit multidimensional therapeutic potential, particularly in idiopathic pulmonary fibrosis (IPF). The gene discussed is EDNRB; the disease is pulmonary fibrosis.